187 related articles for article (PubMed ID: 32127340)
1. Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes.
van Eyk HJ; Paiman EHM; Bizino MB; IJzermans SL; Kleiburg F; Boers TGW; Rappel EJ; Burakiewicz J; Kan HE; Smit JWA; Lamb HJ; Jazet IM; Rensen PCN
Nutr Metab Cardiovasc Dis; 2020 Apr; 30(4):616-624. PubMed ID: 32127340
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients.
van Eyk HJ; Paiman EHM; Bizino MB; de Heer P; Geelhoed-Duijvestijn PH; Kharagjitsingh AV; Smit JWA; Lamb HJ; Rensen PCN; Jazet IM
Cardiovasc Diabetol; 2019 Jul; 18(1):87. PubMed ID: 31288820
[TBL] [Abstract][Full Text] [Related]
3. Twelve weeks of exenatide treatment increases [
Janssen LGM; Nahon KJ; Bracké KFM; van den Broek D; Smit R; Sardjoe Mishre ASD; Koorneef LL; Martinez-Tellez B; Burakiewicz J; Kan HE; van Velden FHP; Pereira Arias-Bouda LM; de Geus-Oei LF; Berbée JFP; Jazet IM; Boon MR; Rensen PCN
Metabolism; 2020 May; 106():154167. PubMed ID: 31982480
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
[TBL] [Abstract][Full Text] [Related]
5. Effect of Liraglutide on Arterial Inflammation Assessed as [
Ripa RS; Zobel EH; von Scholten BJ; Jensen JK; Binderup T; Diaz LJ; Curovic VR; Hansen TW; Rossing P; Kjaer A
Circ Cardiovasc Imaging; 2021 Jul; 14(7):e012174. PubMed ID: 34187185
[TBL] [Abstract][Full Text] [Related]
6. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
[TBL] [Abstract][Full Text] [Related]
7. Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
Jendle J; Hyötyläinen T; Orešič M; Nyström T
Cardiovasc Diabetol; 2021 Dec; 20(1):237. PubMed ID: 34920733
[TBL] [Abstract][Full Text] [Related]
8. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
Horowitz M; Flint A; Jones KL; Hindsberger C; Rasmussen MF; Kapitza C; Doran S; Jax T; Zdravkovic M; Chapman IM
Diabetes Res Clin Pract; 2012 Aug; 97(2):258-66. PubMed ID: 22446097
[TBL] [Abstract][Full Text] [Related]
9. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.
Bizino MB; Jazet IM; Westenberg JJM; van Eyk HJ; Paiman EHM; Smit JWA; Lamb HJ
Cardiovasc Diabetol; 2019 Apr; 18(1):55. PubMed ID: 31039778
[TBL] [Abstract][Full Text] [Related]
10. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
Jendle J; Nauck MA; Matthews DR; Frid A; Hermansen K; Düring M; Zdravkovic M; Strauss BJ; Garber AJ;
Diabetes Obes Metab; 2009 Dec; 11(12):1163-72. PubMed ID: 19930006
[TBL] [Abstract][Full Text] [Related]
11. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
Frøssing S; Nylander M; Chabanova E; Frystyk J; Holst JJ; Kistorp C; Skouby SO; Faber J
Diabetes Obes Metab; 2018 Jan; 20(1):215-218. PubMed ID: 28681988
[TBL] [Abstract][Full Text] [Related]
12. Effects of Capsinoid Intake on Brown Adipose Tissue Vascular Density and Resting Energy Expenditure in Healthy, Middle-Aged Adults: A Randomized, Double-Blind, Placebo-Controlled Study.
Fuse S; Endo T; Tanaka R; Kuroiwa M; Ando A; Kume A; Yamamoto A; Kuribayashi K; Somekawa S; Takeshita M; Hashimoto M; Kime R; Kurosawa Y; Hamaoka T
Nutrients; 2020 Sep; 12(9):. PubMed ID: 32887379
[TBL] [Abstract][Full Text] [Related]
13. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
Mann JFE; Fonseca VA; Poulter NR; Raz I; Idorn T; Rasmussen S; von Scholten BJ; Mosenzon O;
Clin J Am Soc Nephrol; 2020 Apr; 15(4):465-473. PubMed ID: 32132141
[TBL] [Abstract][Full Text] [Related]
14. Exposure-response analyses of liraglutide 3.0 mg for weight management.
Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
[TBL] [Abstract][Full Text] [Related]
15. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.
Bizino MB; Jazet IM; de Heer P; van Eyk HJ; Dekkers IA; Rensen PCN; Paiman EHM; Lamb HJ; Smit JW
Diabetologia; 2020 Jan; 63(1):65-74. PubMed ID: 31690988
[TBL] [Abstract][Full Text] [Related]
16. Effect of L-arginine on energy metabolism, skeletal muscle and brown adipose tissue in South Asian and Europid prediabetic men: a randomised double-blinded crossover study.
Boon MR; Hanssen MJW; Brans B; Hülsman CJM; Hoeks J; Nahon KJ; Bakker C; van Klinken JB; Havekes B; Schaart G; Jazet IM; Rensen PCN; van Marken Lichtenbelt WD
Diabetologia; 2019 Jan; 62(1):112-122. PubMed ID: 30377712
[TBL] [Abstract][Full Text] [Related]
17. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
Lambadiari V; Pavlidis G; Kousathana F; Varoudi M; Vlastos D; Maratou E; Georgiou D; Andreadou I; Parissis J; Triantafyllidi H; Lekakis J; Iliodromitis E; Dimitriadis G; Ikonomidis I
Cardiovasc Diabetol; 2018 Jan; 17(1):8. PubMed ID: 29310645
[TBL] [Abstract][Full Text] [Related]
18. The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.
Flint A; Kapitza C; Zdravkovic M
Diabetes Obes Metab; 2013 Oct; 15(10):958-62. PubMed ID: 23551925
[TBL] [Abstract][Full Text] [Related]
19. Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice.
Heppner KM; Marks S; Holland J; Ottaway N; Smiley D; Dimarchi R; Perez-Tilve D
Diabetologia; 2015 Sep; 58(9):2124-32. PubMed ID: 26049402
[TBL] [Abstract][Full Text] [Related]
20. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.
Beiroa D; Imbernon M; Gallego R; Senra A; Herranz D; Villarroya F; Serrano M; Fernø J; Salvador J; Escalada J; Dieguez C; Lopez M; Frühbeck G; Nogueiras R
Diabetes; 2014 Oct; 63(10):3346-58. PubMed ID: 24917578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
